To appraise the clinical and cost effectiveness of Lenalidomide in combination with R-CHOP chemotherapy within its marketing authorisation for Diffuse Large B-cell Lymphoma
Following on from information provided to NICE by the company in September 2019, the appraisal of Lymphoma (diffuse large B-cell, activated, untreated) - lenalidomide (with R-CHOP) [ID1611] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1611
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Lymphoma (diffuse large B-cell, activated, untreated) - lenalidomide (with R-CHOP) [ID1611] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 September 2019 | Suspended. Referred 18 March 2019 |
| 19 September 2019 | Note added to the project documents |
| 08 May 2019 | In progress. Referred 18 March 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual